The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 04, 2025

Filed:

Jun. 18, 2019
Applicants:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Memgen, Inc., Houston, TX (US);

Inventors:

Amer A. Beg, Tampa, FL (US);

Scott J. Antonia, Durham, NC (US);

Mark J. Cantwell, Meadow Vista, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61K 35/761 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/56 (2006.01); C07K 14/705 (2006.01); C12N 5/0784 (2010.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 35/761 (2013.01); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/464441 (2023.05); A61K 39/464838 (2023.05); A61P 35/00 (2018.01); C07K 14/56 (2013.01); C07K 14/70578 (2013.01); C12N 5/0639 (2013.01); C12N 7/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/585 (2013.01); A61K 2239/57 (2023.05); C12N 2510/00 (2013.01); C12N 2710/10321 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01);
Abstract

The invention concerns APCs, such as DCs, comprising a combination of an exogenous type I interferon and an exogenous CD40-L or one or more heterologous nucleic acid sequences encoding a combination of an exogenous type I IFN and an exogenous CD40-L, such as a combination of IFNβ and CD40-L; and methods for treating a malignancy by administering such APCs to a subject in need thereof. In certain embodiments, a subject is treated with an irradiation therapy before administering the APCs, such as DCs, of the invention. The invention also concerns an oncolytic virus comprising a combination of a type I IFN and CD40-L or one or more nucleic acid sequences encoding a combination of a type I IFN and CD40-L, such as a combination of IFNβ and CD40-L; and methods for treating a malignancy by administering such oncolytic virus to a subject in need thereof.


Find Patent Forward Citations

Loading…